Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SpringWorks Therapeutics (SWTX)

SpringWorks Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SWTX
DateTimeSourceHeadlineSymbolCompany
04/09/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
03/09/202421:09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
03/09/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
28/08/202411:30GlobeNewswire Inc.FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PNNASDAQ:SWTXSpringWorks Therapeutics Inc
07/08/202411:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SWTXSpringWorks Therapeutics Inc
07/08/202411:34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SWTXSpringWorks Therapeutics Inc
07/08/202411:30GlobeNewswire Inc.SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:SWTXSpringWorks Therapeutics Inc
30/07/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SWTXSpringWorks Therapeutics Inc
29/07/202411:30GlobeNewswire Inc.SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of DirectorsNASDAQ:SWTXSpringWorks Therapeutics Inc
23/07/202412:00GlobeNewswire Inc.SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024NASDAQ:SWTXSpringWorks Therapeutics Inc
02/07/202417:49PR Newswire (US)Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law FirmNASDAQ:SWTXSpringWorks Therapeutics Inc
01/07/202411:30GlobeNewswire Inc.SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PNNASDAQ:SWTXSpringWorks Therapeutics Inc
07/06/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SWTXSpringWorks Therapeutics Inc
05/06/202421:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
05/06/202412:00GlobeNewswire Inc.SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:SWTXSpringWorks Therapeutics Inc
03/06/202421:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
23/05/202422:13GlobeNewswire Inc.SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:SWTXSpringWorks Therapeutics Inc
17/05/202421:53Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SWTXSpringWorks Therapeutics Inc
08/05/202412:00GlobeNewswire Inc.SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care ConferenceNASDAQ:SWTXSpringWorks Therapeutics Inc
02/05/202411:30GlobeNewswire Inc.SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business UpdatesNASDAQ:SWTXSpringWorks Therapeutics Inc
24/04/202418:31GlobeNewswire Inc.SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:SWTXSpringWorks Therapeutics Inc
18/04/202412:00GlobeNewswire Inc.SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024NASDAQ:SWTXSpringWorks Therapeutics Inc
04/03/202411:30GlobeNewswire Inc.SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PNNASDAQ:SWTXSpringWorks Therapeutics Inc
01/03/202422:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
29/02/202413:30GlobeNewswire Inc.SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid TumorsNASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202413:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202413:23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202412:29Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202411:51Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202411:44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SWTXSpringWorks Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SWTX

Your Recent History